Vers un nouveau Plyo

Efficacy and safety of novel freeze-dried plasma products in a porcine combat casualty model
Dufour-Gaume F et Al. Transfusion. 2024 Sep;64(9):1670-1682

-----------

Le Plyo est un des produits phares développé par le CTSA. Les recherches continuent pour  améliorer les caractérisques. C'est le sens de ce tavail qui porte sur du Plyo plus concentré ou enrichi en lyophylisat de plaquettes. Ce dernier produit parait particulièrement intéressant. l'industrie pharmaceutique n'est pas en reste puisqu'elle propose maintenant des alternatives au PLyo standard comme l'OctaplastLG considéré comme un médicament et non plus un dérivé du sang.

-----------

Background

Hemorrhagic shock is well documented as a leading cause of preventable fatalities among military casualties. During military operations plasma can be transfused while waiting for whole blood. This study was conducted to assess the safety and efficacy of two new freeze-dried plasma formulations in a porcine model of traumatic hemorrhagic shock.

Study Design and Methods

In the face of species-specific transfusion, transfusible blood products were derived from porcine sources. The efficacy of three lyophilized plasma (LP) formulations was evaluated: lyophilized plasma (LP), concentrated lyophilized plasma (CLP), and platelet-rich concentrated lyophilized plasma (PCLP). Pigs were subjected to multi-trauma and hemorrhagic shock. Ninety minutes post-shock induction, the animals were treated with one of the three lyophilized products. Monitoring included systolic blood pressure and cardiac output. Point-of-care and laboratory diagnostic tests were used to assess renal function, real-time hemostasis (ROTEM), and coagulation. Histological examinations of kidney, lung, and muscle tissues were conducted 4 h after shock induction.

Results

CLP and PCLP significantly improved systolic blood pressure and cardiac output and positively influenced base excess, creatinine, various ROTEM, and coagulation markers compared with standard LP without histologic modification. No adverse effect was associated with the transfusion of any of the plasma products throughout the experimental procedures.

Conclusion

Both CLP and PCLP exhibit promising therapeutic potential for managing hemorrhagic shock in scenario where whole blood supplies are limited. However, the distinct physiological and coagulation characteristics of the swine model necessitate further investigation using humanized preclinical models to fully understand their clinical applicability and constraints